NASDAQ · Biotechnology

Connect Biopharma Holdings Limited (CNTB) Stock

$0.91 +0.01% NASDAQ: CNTB Healthcare

Valuation

MetricValue
Price$0.91
Market Cap$57.07M
P/E Ratio-1.05
P/B Ratio2.17
P/S Ratio19.87
EPS (TTM)$-1.00
52-Week High$3.82
52-Week Low$0.87
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-150.47%
ROA-119.14%
ROCE-194.09%
Gross Margin100.00%
Operating Margin-603.12%
Net Margin-583.50%
Debt/Equity0.02
Current Ratio3.64

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$26.0M$0
Operating Profit$-98.0M$-119.0M$-69.0M$-22.0M$-58.0M
Net Profit$-202.0M$-118.0M$-62.0M$-16.0M$-55.0M
EPS$-25.00$-14.50$-1.08$-0.28$-1.00
Op Margin———-86.2%-90740.6%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$291.0M$174.0M$127.0M$101.0M$56.0M
Total Liabilities$19.0M$17.0M$26.0M$9.0M$14.0M
Cash$268.0M$79.0M$106.0M$78.0M$38.0M
Borrowings$0$0$0$0$1.0M

Latest News

Oppenheimer Initiates Connect Biopharma at Outperform With $8 Price Target MT Newswires · Jul 9, 2026 Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma GlobeNewswire · Jun 17, 2026 Canaccord Genuity Initiates Connect Biopharma at Buy With $6 Price Target MT Newswires · May 26, 2026 Connect Biopharma Touts Rademikibart’s Edge as SEABREEZE Data Looms in 2026 MarketBeat · May 22, 2026 Companies Like Connect Biopharma Holdings (NASDAQ:CNTB) Could Be Quite Risky Simply Wall St. · May 15, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-86.0M$-99.0M$-48.0M$-24.0M$-51.0M
Investing Cash Flow$-13.0M$-88.0M$75.0M$-4.0M$9.0M
Financing Cash Flow$-20.0M$0$0$0$0
Net Cash Flow$109.0M$-169.0M$27.0M$-27.0M$-40.0M
Free Cash Flow$-93.0M$-104.0M$-48.0M$-24.0M$-52.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.01
EV / EBITDA-0.62
FCF Yield-54.70%
Quick Ratio2.37
Interest Coverage—
Return 1Y67.02%
Return 3Y118.06%
Return 5Y-89.75%

Ownership

Insiders Held31.82%
Institutions Held55.58%
Institutions Float Held81.53%
Institutional HolderSharesReport Date
Ikarian Capital, LLC5,388,4862026-03-31
Boothbay Fund Management, LLC1,234,5822026-03-31
683 Capital Management LLC900,0002026-03-31
Perceptive Advisors Llc792,6962026-03-31
Adar1 Capital Management, LLC 742,4002026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ARTVArtiva Biotherapeutics, Inc. $5.85 -3.47% -2.06 $286.01M 0.00%
CNTXContext Therapeutics Inc. $0.24 +1.46% -0.64 $22.42M 0.00%
IFRXInflaRx N.V. $1.32 -8.33% -3.14 $194.53M 0.00%
IMAImageneBio, Inc. $4.04 +0.25% -0.87 $45.86M 0.00%
KLRSKalaris Therapeutics, Inc. $2.00 -8.68% -1.38 $43.68M 0.00%

About Connect Biopharma Holdings Limited

Connect Biopharma Holdings Limited is led by CEO Barry D. Quart, employs 62 people, headquartered in CN, publicly traded since 2021.

Connect Biopharma Holdings Limited (CNTB) stock trades at $0.91 with a market capitalization of $57.07M. The stock is valued at a negative price-to-earnings (P/E) ratio of -1.05, reflecting a net loss over the last twelve months, price-to-book of 2.17, price-to-sales of 19.87. Over the past 52 weeks the stock has ranged between $0.87 and $3.82, and currently trades 76.2% below its 52-week high.

On profitability, Connect Biopharma Holdings Limited generates a return on equity (ROE) of -150.47% (negative, reflecting a net loss), return on capital employed of -194.09%, an operating margin of -603.12%, a net profit margin of -583.50%.

Connect Biopharma Holdings Limited (CNTB) — frequently asked questions

What is Connect Biopharma Holdings Limited (CNTB) stock price today?

Connect Biopharma Holdings Limited (CNTB) is currently trading at $0.91, up 0.01% today.

What is CNTB P/E ratio?

Connect Biopharma Holdings Limited's P/E ratio is -1.05. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.

What is CNTB return on equity (ROE)?

Connect Biopharma Holdings Limited's return on equity (ROE) is -150.47%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.

What is Connect Biopharma Holdings Limited's market cap?

Connect Biopharma Holdings Limited has a market capitalization of $57.07M.

Related Healthcare Stocks

LLY Eli Lilly and Company $1257.03 +0.43% JNJ Johnson & Johnson $255.56 +0.90% ABBV AbbVie Inc. $285.42 +0.71% UNH UnitedHealth Group Incorporated Common Stock (DE) $401.43 -1.29% MRK Merck & Company, Inc. Common Stock (new) $145.97 +0.53% NVS Novartis AG $150.62 +0.16% AZN AstraZeneca PLC $165.41 -0.76% TMO Thermo Fisher Scientific Inc $690.00 -0.93% AMGN Amgen Inc. $432.49 -0.35% GILD Gilead Sciences, Inc. $156.19 -0.75% ABT Abbott Laboratories $104.88 +0.19% NVO Novo Nordisk A/S $38.83 -0.99%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.